2016 Press Releases| Newsroom | Medtronic

2016 Press Releases


201620152014201320122011
Search News Releases
 
DateTitle  
12/01/16Medtronic Announces Reimbursement Approval and Launch of CoreValve(TM) Evolut(TM) R System in Japan
Medtronic Introduces First-and-Only Recapturable TAVI System Available in Japan DUBLIN - Dec. 1, 2016 - Medtronic plc (NYSE: MDT) today announced it has received reimbursement approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the recapturable, self-expanding transcatheter CoreValve(TM) Evolut(TM) R System for patients with severe aortic stenosis (AS) unable to undergo surgery, and for whom treatment with transcatheter aortic valve implantation (TAVI) is determined to b... 
 Printer Friendly Version
11/29/16Medtronic Announces U.S. Launch of Integrated Health Solutions with University Hospitals Agreement
New Agreement Focuses on Improved System Efficiency at University Hospitals Cleveland Medical Center DUBLIN and CLEVELAND - Nov. 29, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the signing of its first Integrated Health Solutions agreement in the United States with University Hospitals (UH), one of the nation's leading healthcare systems, designed to improve delivery of care and patient experience. Together the organizations will implement innovativ... 
Download PDFPrinter Friendly Version
11/29/16Medtronic First to Receive European Approval for Less-Invasive HVAD® Implant Procedure
New Implant Option Gives Physicians Surgical Alternative for Patients with Advanced Heart Failure DUBLIN - Nov. 29, 2016 - Medtronic plc (NYSE: MDT) today announced that its HVAD® System left ventricular assist device (LVAD) received CE (Conformité Européenne) Mark for a less-invasive implant procedure in patients with advanced heart failure. The HVAD System is the only centrifugal LVAD approved in the European Union for implantation via this new thoracotomy procedure. Compared to the standard... 
 Printer Friendly Version
11/22/16Medtronic Reports Second Quarter Financial Results
Revenue of $7.3 Billion Grew 4% as Reported; 3% at Constant Currency GAAP Diluted EPS of $0.80; Non-GAAP Diluted EPS of $1.12 GAAP Diluted EPS Grew 122%; Non-GAAP EPS Grew 15% at Constant Currency GAAP Operating Margin Improved 50 bps; Non-GAAP Operating Margin Improved 150 bps DUBLIN - November 22, 2016 - Medtronic plc (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2017, which ended October 28, 2016. The company reported second quarter worldwide rev... 
 Printer Friendly Version
11/17/16New Data Show Medtronic Heli-FX EndoAnchor System Enhances Outcomes and Durability in Complex Aortic Disease
Data from ANCHOR Registry Demonstrate Applicability in Patients with Hostile Aortic Neck Anatomy  DUBLIN and NEW YORK - Nov. 17, 2016 - Medtronic plc (NYSE: MDT) today announced data demonstrating that the company's Heli-FX(TM) EndoAnchor(TM) system enhances outcomes and durability in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those who have hostile aortic neck anatomy. The new data were presented in a series of three different presentations during the 43rd Annu... 
 Printer Friendly Version
11/16/16Medtronic Releases FY16 Integrated Performance Report
Report Highlights Company's Global Financial, Social, and Environmental Impact DUBLIN - Nov. 16, 2016 - Medtronic plc (NYSE:MDT) announces the release of its 2016 Integrated Performance Report. The report highlights - for the first time - the combined financial, social, and environmental impact of Medtronic after acquiring Covidien in 2015. The FY 2016 Integrated Performance Report details the company's commitment to addressing business and industry challenges. Based on the Global Reporting In... 
 Printer Friendly Version
11/16/16Medtronic's Solitaire(TM) Stent Retriever Device Receives Expanded Indication from the U.S. Food and Drug Administration for the Reduction of Stroke-Related Disability
FDA Allows Use of the Most Studied Stent Retriever with IV-tPA DUBLIN - Nov. 16, 2016 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded indication for the Solitaire(TM) stent retriever device. The FDA now allows the marketing of the Solitaire device as an initial therapy for acute ischemic strokes (AIS) for patients with a persistent, proximal anterior circulation, large vessel occlusion, and smaller core infarcts to reduce pa... 
Download PDFPrinter Friendly Version
11/15/16Medtronic's Endurant(TM) II/IIs Stent Graft System Delivers Positive Outcomes in Patients with Challenging Aortic Aneurysms
New Data from the Global ENGAGE Registry Builds on Durability of Endurant, with Strong Outcomes Out to Four Years in Patients with Standard and Hostile Neck Anatomies DUBLIN - Nov. 15, 2016 - Medtronic plc (NYSE:MDT) today announced data supporting the strength and durability of the Endurant(TM) II/IIs1 stent graft system to treat abdominal aortic aneurysm (AAA) patients. The results, presented during the 43rd Annual Symposium of Vascular and Endovascular Issues (VEITHsymposium) in New York, ar... 
 Printer Friendly Version
11/14/16Medtronic to Unveil Data Supporting Endovascular Treatments for Aortic Disease at VEITHsymposium 2016
DUBLIN - Nov. 14, 2016 - Medtronic plc (NYSE: MDT) today announced notable presentations of clinical studies on how endovascular treatments are furthering the treatment of core and complex aortic disease at the 43rd Annual Symposium of Vascular and Endovascular Issues (VEITHsymposium), the world's largest educational meeting specializing in vascular surgical medicine in New York from November 14 - 19, 2016. This year, Medtronic's aortic technologies will be featured in more than 30 presentation... 
 Printer Friendly Version
11/14/16Medtronic Receives FDA Approval for Claria MRI(TM) Quad Cardiac Resynchronization Therapy Defibrillator
First CRT-D in U.S. to Help Improve Therapy Delivery in Heart Failure Patients Using Effective Pacing DUBLIN - Nov. 14, 2016 - Medtronic plc (NYSE:MDT) has received U.S. Food and Drug Administration (FDA) approval for the Claria MRI(TM) Quad Cardiac Resynchronization Therapy Defibrillator (CRT-D) SureScan(TM) device for patients with heart failure. The Claria MRI CRT-D is approved for scanning in both 1.5 and 3 Tesla (T) magnetic resonance imaging (MRI) machines, and features EffectivCRT(TM), ... 
 Printer Friendly Version
11/11/16Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2017
DUBLIN - Nov. 11, 2016 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for its second quarter of fiscal year 2017 on Tuesday, November 22, 2016. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company's second quarter of fiscal year 2017, which ended on Friday, October 28, 2016. Medtronic will host a w... 
Download PDFPrinter Friendly Version
11/10/16Medtronic Launches Orthopedic Solutions Business to Help Providers Deliver Outcome-Focused Care and Succeed in New Value-Based Bundled Service Models
Orthopedic Solutions Offers Comprehensive Services for Joint Replacement Episodes of Care, Including the Launch of a Total Knee Arthroplasty System DUBLIN and DALLAS - Nov. 10, 2016 - Medtronic plc (NYSE: MDT) today announced the launch of Medtronic Orthopedic Solutions, a comprehensive offering for total joint replacement episodes of care designed to drive clinical and economic outcomes. This offering is in response to the high costs associated with hip and knee replacements, along with the gr... 
 Printer Friendly Version
11/01/16Medtronic Harmony(TM) Transcatheter Pulmonary Valve Demonstrates Positive Early Clinical Outcomes at One Year
FDA Approves IDE Study Initiation Following Positive Results from First-of-its-Kind Early Feasibility Study Presented at TCT DUBLIN and WASHINGTON, D.C. - Nov. 1, 2016 - Medtronic plc (NYSE: MDT) today announced new clinical data for the Harmony(TM) Transcatheter Pulmonary Valve (TPV) from its early feasibility study, showing improved hemodynamics from baseline and consistent valve performance at one year. Presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, th... 
Download PDFPrinter Friendly Version
11/01/16Medtronic CoreValve(TM) Evolut R(TM) System Shows Exceptional Clinical Outcomes at One Year
New Data from Evolut R U.S. IDE study presented at TCT Reveals Positive Clinical Performance for the Recapturable TAVR Device, Including the First-of-its-Kind 34 mm Valve DUBLIN and WASHINGTON, D.C. - Nov. 1, 2016 - Medtronic plc (NYSE: MDT) unveiled new clinical data showing that patients treated with the self-expanding CoreValve(TM) Evolut(TM) R System continued to experience excellent clinical outcomes at one year.  As the first-and-only recapturable transcatheter aortic valve replacement (T... 
Download PDFPrinter Friendly Version
10/31/16First Clinical Data of Medtronic Drug-Filled Stent Show Positive Outcomes
Featured 'First Report' RevElution Trial at TCT Highlights the Potential Benefits of First-of-its-Kind Polymer-Free Technology with Controlled and Sustained Drug Delivery for Rapid Vessel Healing DUBLIN and WASHINGTON, D.C. - Oct. 31, 2016 - Medtronic plc (NYSE: MDT) unveiled today the first clinical outcomes of its novel Drug-Filled Stent (DFS) from the RevElution Trial at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Also published simultaneously in the Journal of ... 
Download PDFPrinter Friendly Version
10/31/16New Data on Medtronic Evolut(TM) R TAVR System Show Excellent 'Real-World' Outcomes in Global Patient Population
Results from FORWARD and STS/ACC TVT Registry Demonstrate High Survival and Low Rate of All Stroke for Next-Generation TAVR Device in Everyday Clinical Practice DUBLIN and WASHINGTON, DC - Oct. 31, 2016 - Medtronic plc (NYSE: MDT) today presented new positive data from two large registries aimed at evaluating 30-day clinical performance outcomes for the self-expanding, recapturable and repositionable CoreValve(TM) Evolut(TM) R System in "real-world" severe aortic stenosis patient popu... 
Download PDFPrinter Friendly Version
10/30/16Independent Study Finds Biodegradable Polymer Stents Provide No Clinical Benefit Over Resolute Integrity(TM) DES
BIO-RESORT Demonstrates Excellent Clinical Outcomes for Medtronic Resolute(TM) Integrity(TM) DES, a Gold Standard for Percutaneous Coronary Intervention DUBLIN and WASHINGTON, DC - Oct. 30, 2016 - Investigators today unveiled clinical data from the independent BIO-RESORT study, representing the first all-comers analysis to compare the safety and efficacy of biodegradable polymer stents (BP-DES) to durable polymer Resolute(TM) Integrity(TM) drug-eluting stent (DP-DES) from Medtronic plc (NYSE: M... 
Download PDFPrinter Friendly Version
10/27/16The World Stroke Organization Road Map for Quality Stroke Care Has Been Launched
Medtronic joins the Global Framework for Stroke Care on World Stroke Day DUBLIN and HYDERABAD, India - Oct. 27, 2016 - In recognition of World Stroke Day, Medtronic plc (NYSE:MDT) and the World Stroke Organization (WSO) joined together for the third year to raise awareness of stroke and discuss the Road Map for Quality Stroke Care at a press conference held today at the World Stroke Congress in Hyderabad, India. Yesterday, WSO launched the Road Map, which provides the framework for the implemen... 
Download PDFPrinter Friendly Version
10/26/16Medtronic Announces FDA Approval of New Recaptureable TAVR System Available for Severe Aortic Stenosis Patients with Large Anatomies
Launch of 34 mm Self-Expanding Evolut R Device Expands TAVR Treatment to Patients Who Could Not be Treated Previously DUBLIN - Oct. 26, 2016 - Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve(TM) Evolut(TM) R 34 mm valve-the largest sized transcatheter aortic valve replacement (TAVR) system available in the U.S. The new Evolut R 34 mm valve is approved for severe aortic stenosis patients who are at high or extreme ris... 
Download PDFPrinter Friendly Version
10/24/16Medtronic Receives FDA Clearance of New Lower Profile HawkOne 6F Directional Atherectomy System
New Technology Expands Treatment Options for Patients with Peripheral Artery Disease Both Above and Below the Knee DUBLIN - Oct. 24, 2016 - Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the HawkOne(TM) Directional Atherectomy System in a new size for treating patients with peripheral artery disease (PAD). The HawkOne system is designed to remove plaque from the vessel wall and restore blood flow. The new HawkOne 6 French (6F) provides an ef... 
Download PDFPrinter Friendly Version
10/24/16MiniMed® Connect Mobile Accessory for Android Now Available from Medtronic
MiniMed Connect Mobile Accessory Provides Easier and Better Access to Pump and CGM Data, Helping Optimize Therapy for Improved Glycemic Patterns DUBLIN - October 24, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. commercial availability of the Android(TM) operating system version of the MiniMed Connect mobile accessory, the first and only product enabling people with diabetes to see their real-time glucose level  on Android mobile devices. The M... 
Download PDFPrinter Friendly Version
10/21/16Medtronic to Webcast Investor and Analyst Briefings on October 26, 2016 and October 30, 2016
DUBLIN - Oct. 21, 2016 - Medtronic plc  (NYSE:MDT) today announced the company will webcast investor and analyst briefings at two upcoming medical conferences. Medtronic will host a webcast to provide an update on its Restorative Therapies Group during the North American Spine Society (NASS) 2016 Annual Meeting on Wednesday, October 26, 2016, in Boston from 10:30 a.m. - 12:00 p.m.  EDT.  The webcast can be accessed by clicking on the Investor Events link at http://investorrelations.medtronic.com... 
Download PDFPrinter Friendly Version
10/14/16Medtronic Announces Voluntary Recall of Its Pipeline(TM) Embolization Device, Alligator(TM) Retrieval Device, X-Celerator(TM) Hydrophilic Guidewire, Ultraflow(TM) and Marathon(TM) Flow Directed Micro Catheters
DUBLIN - Oct. 14, 2016 - Medtronic plc (NYSE: MDT) today announced that it has notified customers of a voluntary recall of certain lots of its Pipeline(TM) embolization device, Alligator(TM) retrieval device and X-Celerator(TM) hydrophilic guidewire. The recall also includes the stylet containing UltraFlow(TM) flow directed micro catheters and Marathon(TM) flow directed micro catheters. These products are produced, marketed and sold by Medtronic's Neurovascular business, which is part of the Bra... 
Download PDFPrinter Friendly Version
10/13/16Medtronic Cardiac Devices Gain FDA Approval to Enable Patient Access to the Most Advanced Diagnostic Imaging
Patients with SureScan® Pacemakers, ICDs and CRT-Ds Now Can Receive 3 Tesla MRI Scans DUBLIN - Oct. 13, 2016 - Medtronic plc (NYSE:MDT) is the first company to receive U.S. Food and Drug Administration (FDA) approval for its suite of cardiac rhythm and heart failure devices and leads to be scanned in both 3 and 1.5 Tesla (T) magnetic resonance imaging (MRI) machines. This advancement gives patients with Medtronic SureScan® MR-conditional pacemakers, implantable cardioverter-defibrillators (ICDs... 
Download PDFPrinter Friendly Version
10/13/16FIRE AND ICE Analysis: Lower Healthcare System Costs with Medtronic Cryoballoon
Late Breaking Clinical Trial Demonstrates Favorable Health Economics and Positive Clinical Outcomes for AF Patients DUBLIN AND SEOUL, REPUBLIC OF KOREA - Oct. 13, 2016 - Medtronic plc (NYSE:MDT) today unveiled new health economic analysis data from the FIRE AND ICE trial that favor cryoballoon catheter ablation over radiofrequency (RF) ablation related to trial period cost savings as a result of fewer cardiovascular (CV) rehospitalizations and repeat ablations. The data were presented at a late... 
Download PDFPrinter Friendly Version
10/03/16Medtronic Avalus(TM) Surgical Aortic Valve Shows Positive Outcomes in One-Year Clinical Trial Results
Presented at EACTS, First Data of New Pericardial Heart Valve Finds High Survival and Excellent Hemodynamics DUBLIN and BARCELONA - Oct. 3, 2016 - Medtronic plc (NYSE: MDT) today announced positive clinical data for its investigational Avalus(TM) pericardial aortic surgical valve, intended for the treatment of aortic valve disease. Presented at the 30th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting for the first time, results from the PERIGON (PERIcardial SurGical AO... 
Download PDFPrinter Friendly Version
09/30/16FDA Classifies Two Field Actions Related to HeartWare HVAD System as Class 1 Recalls
DUBLIN - Sept. 30, 2016 - Medtronic plc (NYSE:MDT) announced today that two previously communicated global voluntary recalls related to the HeartWare International (HeartWare) HVAD® System have been classified as Class 1 by the U.S. Food and Drug Administration (FDA). Class 1 recalls describe situations where there is reasonable risk of serious adverse health consequences or death. In a safety notification letter distributed globally in May and June 2016, HeartWare® notified physicians regardin... 
Download PDFPrinter Friendly Version
09/28/16Medtronic Receives FDA Approval for World's First Hybrid Closed Loop System for People with Type 1 Diabetes
The MiniMed® 670G System Features the Company's Most Advanced SmartGuard(TM) Algorithm To-Date DUBLIN - Sept. 28, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed® 670G system - the first Hybrid Closed Loop insulin delivery system approved anywhere in the world. Featuring the company's most advanced algorithm - SmartGuard(TM) HCL - the system is the latest innovation in Medtr... 
Download PDFPrinter Friendly Version
09/28/16Medtronic Receives FDA Clearance of TrailBlazer Angled Peripheral Support Catheter
TrailBlazer Angled Support Catheter Broadens Medtronic's Leading Peripheral Options Adding Full Spectrum of Angled Resources to Meet Provider Needs DUBLIN - September 28, 2016 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the TrailBlazer(TM) angled support catheter for use in the peripheral vascular system. Support catheters such as the Trailblazer are often used in endovascular procedures treating complex peripheral artery disease (PA... 
Download PDFPrinter Friendly Version
09/27/16Medtronic Announces First Live Experience of Sugar.IQ with Watson for People Living with Diabetes
Sugar.IQ with Watson Cognitive App to Preview at Health 2.0 Conference DUBLIN and SANTA CLARA, Calif. - Sept. 27, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that Sugar.IQ with Watson, the first-of-its-kind cognitive app that helps detect important patterns and trends for people with diabetes, is now in live use for the first time. With app development now completed, the first users are participating in real-world testing of the final release candi... 
Download PDFPrinter Friendly Version
09/26/16Medtronic's StealthStation® Cranial Software Receives FDA Clearance as an Aid for Deep Brain Stimulation Lead Placement
The Company Continues to Pioneer Innovations in Deep Brain Stimulation and Surgical Technologies by Launching the Only Fully-Integrated Procedural Solution for Neurosurgery DUBLIN and SAN DIEGO - September 26, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) clearance of StealthStation® Cranial Software as an aid for deep brain stimulation (DBS) lead placement. The software is fully integrated with Medtronic's latest O-arm® Imaging System, providing clini... 
Download PDFPrinter Friendly Version
09/20/16Medtronic Valiant Captivia Demonstrates Safety and Efficacy at Three Years
New Clinical Data Presented in Complicated Type B Aortic Dissection at VIVA 2016 DUBLIN and LAS VEGAS - Sept. 20, 2016 - Medtronic plc (NYSE: MDT) today announced new data, demonstrating safety and efficacy at three years in acute complicated Type B aortic dissection patients treated with the Valiant® Captivia® Thoracic Stent Graft System. Ali Azizzadeh, MD, FACS, University of Texas Health Science Center in Texas presented the new clinical data in a late-breaking trial session at Vascular Inter... 
 Printer Friendly Version
09/19/16New Data Presented in VIVA Late Breaking Clinical Trials Demonstrate Durability, Safety and Efficacy for the Medtronic In.Pact Admiral DCB
Multiple, Rigorous Analyses Reinforce the Excellent Outcomes of IN.PACT Admiral Drug Coated Balloon and Differentiate it as Best-in-Class Treatment Option for PAD  DUBLIN and LAS VEGAS - September 19, 2016 - Medtronic today reinforced the superior durability, consistency, and safety of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The new data, presented in a series of late-breaking clinical trial presentations at the Vascular Interventional Ad... 
Download PDFPrinter Friendly Version
09/19/16Analysis Shows Positive Association Between Cardiac Resynchronization Therapy and Patients' Increased Adherence to Heart Failure Medication Regimens
DUBLIN and ORLANDO, Fla. - Sept. 19, 2016 - Medtronic plc (NYSE:MDT) announced the results of an analysis that reveals patients increasingly adhere to heart failure medications after they receive cardiac resynchronization therapy (CRT) devices. The analysis of more than 4,500 patients  revealed that compliance with their medications increased 67 percent 24 months after receiving their CRT implants, compared to the 24 months prior to implant (p<0.001). The results were presented at the 2016 He... 
Download PDFPrinter Friendly Version
09/15/16The Journal of the American Medical Association Publishes Medtronic's Hybrid Closed Loop System Pivotal Trial Results
DUBLIN - September 15, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the publication of its Hybrid Closed Loop system pivotal trial results in the Journal of the American Medical Association (JAMA). The data presented the safety of the system and showed that patients on the therapy experienced less glycemic variability, more time in the target range, less exposure to hypoglycemia and hyperglycemia, and reduced A1c compared to baseline... 
Download PDFPrinter Friendly Version
09/15/16Medtronic Names Mark Ploof Senior Vice President of Global Operations and Business Services
Dublin - September 15, 2016 - Medtronic (NYSE: MDT) today announced the appointment of Mark Ploof as Senior Vice President, Global Operations and Business Services effective October 31, 2016.  He will serve on the company's Executive Committee and be responsible for leading Medtronic's Global Operations, Information Technology, Facilities & Real Estate and Medtronic Business Services functions, which include the company's ongoing Covidien acquisition integration efforts. Ploof succeeds Gary Elli... 
Download PDFPrinter Friendly Version
09/14/16Medtronic Announces Approval and Launch of Reveal LINQ(TM) Insertable Cardiac Monitor in Japan
Miniaturized Device Now Available for Use in Patients with Unexplained Syncope and Stroke  DUBLIN - Sept. 14, 2016 - Medtronic plc (NYSE: MDT) today announced it has received Ministry of Health, Labor and Welfare (MHLW) approval of the Reveal LINQ Insertable Cardiac Monitor (ICM) System in Japan. In addition, MHLW has granted reimbursement approval for Reveal LINQ as a result of work with the Japanese regulatory body.  The device will be available in Japan beginning this month. The Reveal LINQ I... 
Download PDFPrinter Friendly Version
09/13/16Medtronic Foundation Issues $250,000 in Health Access Grants to Support Local Diabetes Services in Northridge, California
Medtronic Foundation Grants Support Organizations Committedto Expanding Healthcare Access NORTHRIDGE, Calif. - Sept. 13, 2016 - Medtronic Foundation today announced that five community organizations will receive a combined $250,000 in Health Access Grants in recognition of their continued commitment to expanding access to healthcare and promoting healthy lifestyles in Los Angeles. Each organization will use these grants for up to two years for the continued work in their respective programs to... 
Download PDFPrinter Friendly Version
09/13/16Medtronic Receives FDA Approval of First Drug-Coated Balloon for Treatment of In-Stent Restenosis (ISR)
IN.PACT Admiral DCB Indication Expansion to Treat Patients with ISR DUBLIN - Sept. 13, 2016 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) as a treatment for in-stent restenosis (ISR) in patients with peripheral artery disease (PAD). This is the first DCB that has gained approval to treat ISR in the U.S. FDA approval was based on ISR data from the IN.PACT Global Study compared to a stan... 
Download PDFPrinter Friendly Version
09/12/16New ESC Guidelines Support Recent Medtronic Innovations for Patients with Atrial Fibrillation
Clinical Practice Guidelines from European Society of Cardiology 2016 Reinforce Benefits of Cryoballoon Ablation and Long-Term Cardiac Monitoring DUBLIN - September 12, 2016 -   Two Medtronic plc (NYSE: MDT) innovations were acknowledged in updated guidelines published by the European Society of Cardiology (ESC): cryoballoon ablation for patients with diagnosed atrial fibrillation (AF), and long-term cardiac monitoring for survivors of stroke who do not have an established diagnosis of AF. The C... 
Download PDFPrinter Friendly Version
09/08/16Medtronic Recognized as a Sustainability Leader
Company named to the Dow Jones Sustainability North America Index (DJSI North America)  DUBLIN - September 8, 2016 - Medtronic plc (NYSE: MDT) was recognized today as one of the world's leading companies for sustainability with its ranking on the Dow Jones Sustainability North America Index (DJSI North America) for the ninth consecutive year.  DJSI North America analyzes companies on a variety of sustainability criteria, including economic performance, environmental stewardship an... 
Download PDFPrinter Friendly Version
09/06/16Medtronic CEO Omar Ishrak to Speak at Morgan Stanley Global Healthcare Conference
DUBLIN - Sept. 6, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced that it will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016, in New York. Omar Ishrak, chairman and chief executive officer of Medtronic, will answer questions about the company beginning at 8:35 a.m. Eastern Daylight Time. A live audio webcast of the presentation will be available on September 13, 2016, by clicking o... 
Download PDFPrinter Friendly Version
09/01/16Medtronic EVP & RTG President Geoff Martha to Speak at Wells Fargo Global Healthcare Conference
DUBLIN - Sept. 1, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced that it will participate in the Wells Fargo Global Healthcare Conference on Thursday, September 8, 2016, in Boston. Geoff Martha, executive vice president and president of the Medtronic Restorative Therapies Group (RTG), will answer questions about the company beginning at 8:45 a.m. Eastern Daylight Time. A live audio webcast of the presentation will be available ... 
Download PDFPrinter Friendly Version
09/01/16Medtronic Announces Approval of Enlite® Sensor for iPro®2 Professional Continuous Glucose Monitoring System in the U.S.
iPro2 Professional CGM with Enlite Provides Critical Link Between Glucose Variability and Lifestyle for Improved Diabetes Control DUBLIN - Sept. 1, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the FDA approval of the Enlitesensor for use with iPro2 Professional Continuous Glucose Monitoring (CGM) system, a market-leading CGM system that enables healthcare providers to obtain a more complete picture of glucose control for the diabetes patients they tr... 
Download PDFPrinter Friendly Version
08/29/16Medtronic Technologies Improve Delivery of Cardiac Resynchronization Therapy
First-of-its-Kind Data on EffectivCRT(TM) for Heart Failure Patients with Atrial Fibrillation Presented at ESC DUBLIN and ROME - Aug. 29, 2016 - Medtronic plc (NYSE:MDT) today announced results from the Cardiac Resynchronization Therapy Efficacy Enhancement (CRTee) study. The study showed that the Medtronic-exclusive device-based EffectivCRT(TM) during AF algorithm improves therapy delivery in heart failure patients with atrial fibrillation (AF). The results were presented at the 2016 European... 
Download PDFPrinter Friendly Version
08/28/16New Long-Term Data Reinforce Safety Benefits of the World's Smallest Pacemaker
Results Featured at ESC 2016 Demonstrate Consistent, Sustained Safety and Effectiveness for the Medtronic Micra TPS DUBLIN and ROME - AUGUST 28, 2016 - In the largest and longest clinical evaluation of leadless pacing patients to date, Medtronic plc (NYSE: MDT) today announced new long-term results from the Medtronic Micra® Transcatheter Pacing System (TPS) Global Clinical Trial in a clinical trial update late-breaking session at the 2016 European Society of Cardiology (ESC) Congress in Rome.... 
Download PDFPrinter Friendly Version
08/26/16Medtronic, on Behalf of Its Subsidiary Heartware International, Inc., Announces Offer to Repurchase HeartWare's 3.50% Convertible Senior Notes Due 2017 and 1.75% Convertible Senior Notes Due 2021
DUBLIN - Aug. 26, 2016 - Medtronic plc (NYSE: MDT), on behalf of its indirect, wholly-owned subsidiary HeartWare International, Inc., today announced that, in connection with the completion of the acquisition of HeartWare by Medtronic, HeartWare has commenced an offer to repurchase (the "Convertible Notes Repurchase Offer"), at the option of each holder, any and all of its outstanding 3.50% Convertible Senior Notes due 2017 (the "2017 Notes") and 1.75% Convertible Senior Note... 
Download PDFPrinter Friendly Version
08/25/16Medtronic Reports First Quarter Financial Results
Revenue of $7.2 Billion Decreased 1% as Reported; Prior Year Had Extra Selling Week Revenue Increased Greater than 5 Percent on a Constant Currency, Constant Weeks Basis GAAP Diluted EPS of $0.66; Non-GAAP Diluted EPS of $1.03 GAAP Cash Flow from Operations of $1.6 Billion; Free Cash Flow of $1.2 Billion Company Reiterates FY17 Revenue Outlook and EPS Guidance  DUBLIN - August 25, 2016 - Medtronic plc (NYSE: MDT) today announced financial results for its first quarter of fiscal year 20... 
 Printer Friendly Version
08/23/16Medtronic Completes Acquisition of HeartWare International
Broadens Heart Failure Leadership Into Growing Circulatory Support Sector DUBLIN - Aug. 23, 2016 - Medtronic plc (NYSE: MDT), the global leader in medical technology, has completed its acquisition of HeartWare International, Inc., a leading innovator of less-invasive, miniaturized, mechanical circulatory support technologies (MCS) for treating patients with advanced heart failure. HeartWare will become part of the Heart Failure business within the Medtronic Cardiac Rhythm and Heart Failure divi... 
Download PDFPrinter Friendly Version
08/19/16Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2017
DUBLIN - August 19, 2016 - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2017 second quarter cash dividend of $0.43 per ordinary share, representing a 13 percent increase over the prior year.  This quarterly declaration is consistent with the dividend announcement made by the company in June 2016.  Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 39 consecutive years.  The dividend ... 
Download PDFPrinter Friendly Version
08/16/16Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2017
DUBLIN - Aug 16, 2016 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for the first quarter of fiscal year 2017, on Thursday, August 25, 2016. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company's first quarter of fiscal year 2017, which ended on Friday, July 29, 2016. Medtronic will host a webcast... 
Download PDFPrinter Friendly Version
08/11/16Medtronic Announces U.S. Launch of the MiniMed® 630G System with New User-Friendly Insulin Pump Design and SmartGuard(TM) Technology
DUBLIN - August 11, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. commercial launch of its MiniMed 630G system with SmartGuard technology FDA approved for the treatment of people with diabetes mellitus sixteen years of age and older. The MiniMed 630G features a new insulin pump hardware platform and new user-friendly design that combines personalized diabetes management with industry-leading clinical performance. The MiniMed 630G system is the... 
Download PDFPrinter Friendly Version
08/08/16Medtronic Receives CE Mark for SureTune2(TM) for Deep Brain Stimulation Therapy
New Visual-Based Platform Helps Physicians Make Informed Programming Decisions by Providing an Intuitive Visualization of Patient-Specific Images and Data DUBLIN - August 8, 2016 - Medtronic plc (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for SureTune2(TM) software, which provides patient-specific visualization to help physicians make decisions on how to program - or tune  - their patient's deep brain stimulation (DBS) therapy.  SureTune2 is currently not approve... 
Download PDFPrinter Friendly Version
08/01/16Medtronic CoreValve(TM) Evolut(TM) R System First TAVI to Receive CE Mark for Intermediate Risk Aortic Stenosis Patients
Next-Generation Recapturable Device is the First-of-its-Kind Approved in Europe to Treat Intermediate Risk Patients as an Alternative to Open-Heart Surgery DUBLIN - August 1, 2016 - Medtronic plc (NYSE: MDT) today announced CE (Conformité Européenne) mark for the self-expanding, recapturable and repositionable CoreValve(TM) Evolut(TM) R System to treat aortic stenosis patients who are at intermediate risk for open-heart surgery as determined by a heart team. The Evolut R System is the first tra... 
Download PDFPrinter Friendly Version
07/27/16REALITY Trial Enrolls First Patient in Study Evaluating Medtronic Directional Atherectomy and Drug-Coated Balloon in PAD Treatment
VIVA Sponsored REALITY Study Assessing Vessel Preparation and Treatment in Severe Calcified Lesions Expands to Germany; Principal Investigators Named; First Patient Enrolled DUBLIN and SAN JOSE, Calif. -July 27, 2016 - Medtronic plc (NYSE: MDT) and VIVA Physicians today report the first patient enrolled in the REALITY Study. The VIVA sponsored study is assessing outcomes for patients with significantly calcified and symptomatic femoropopliteal peripheral artery disease (PAD), following adjuncti... 
Download PDFPrinter Friendly Version
07/25/16Medtronic Unveils VariLoc Variable Angle Locking Technology for Treatment of Fractures
DUBLIN and SHANGHAI - July 25, 2016 - Medtronic plc (NYSE: MDT) today announced the global launch of VariLoc Locking Compression Plate System in China and other select countries. With the innovative variable angle locking technology, the system enables surgeons to adapt screw angulations to patient anatomy, capture fracture fragments, fine-tune screw trajectory after plate placement, and position screws precisely to avoid unnecessary penetration of the nearby joints. The VariLoc system is being ... 
Download PDFPrinter Friendly Version
07/20/16Medtronic Receives First-Ever FDA Clearance for Cement-Augmented Pedicle Screws
  Clearance Gives Spine Surgeons a New Treatment Option for Spinal Tumor Patients DUBLIN - July 20, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the CD Horizon® Fenestrated Screw Set, which can be used for patients diagnosed with advanced stage tumors involving the thoracic and lumbar spine. This marks the first U.S. clearance for cement-augmented pedicle screws. The CD Horizon® Fenestrated Screws are used with Medtronic's HV... 
Download PDFPrinter Friendly Version
07/19/16Medtronic Expands Continuous Glucose Monitoring (CGM) Solutions for People with Diabetes Using Insulin Injections with CE Mark Receipt
New Guardian(TM) Connect System Will Be Launched in Q2 FY17 Outside the U.S. DUBLIN - July 19, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for its new Guardian(TM) Connect mobile continuous glucose monitoring (CGM) system for people with diabetes using insulin injection therapy. Guardian Connect is the first smartphone-enabled CGM system from Medtronic to receive CE Mark and further demonstrates the co... 
Download PDFPrinter Friendly Version
07/18/16Medtronic Receives FDA Approval for Two-Level Prestige LP(TM) Cervical Disc Procedures
Two-Level Use of Prestige LP Cervical Disc Exhibited Statistical Superiority in Overall Success at 24 Months Compared to Patients Treated with Two-Level Fusion DUBLIN - July 18, 2016 - Medtronic plc (NYSE: MDT) announced today the U.S. Food and Drug Administration's (FDA) approval of the Prestige LP(TM) Cervical Disc for the treatment of cervical disc disease causing nerve or spinal cord compression at two adjacent levels between the C3-C7 segments of the neck. The Prestige LP Disc is designed ... 
Download PDFPrinter Friendly Version
07/15/16Medtronic Foundation Calls for Applications for 2016 Bakken Invitation Award
International Award Honors the Philanthropic Power of Patients; At Least 10 Honorees Will Each Receive a $20,000 Grant Donated to an Eligible Charity Organization of Their Choice DUBLIN - July 15, 2016 - The Medtronic Foundation is seeking applications for the 2016 Bakken Invitation Award - an international program honoring and connecting people who have overcome health challenges with the help of medical technology and are selflessly giving back to populations and communities in need. Curren... 
Download PDFPrinter Friendly Version
07/15/16Medtronic Launches Revamped Minimally Invasive Spine Fusion Procedures
Innovative Procedural Solutions Offer Efficiencies for Surgeons Using a Lateral Approach DUBLIN - July 15, 2016 - Medtronic plc (NYSE: MDT) today announced the continued development of the OLIF Platform with the launch of the PivoxTM Oblique Lateral Spinal System with Lateral Plate for OLIF25TM and Divergence-LTM Anterior/Oblique Lumbar Fusion System for OLIF51TM at the International Meeting on Advanced Spine Techniques (IMAST) in Washington, D.C. Lumbar interbody fusions aim to stabilize the b... 
Download PDFPrinter Friendly Version
07/13/16Medtronic Receives FDA Approval for IN.PACT Admiral DCB 150 mm Lengths
Expanded Treatment Options for Patients with Longer SFA Lesions with Best-In-Class Drug-Coated Balloon Technology Now Available DUBLIN - July 13, 2016 - Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in longer, 150 mm lengths. The new 150 mm length balloon, available in four, five, and six mm diameters, will provide greater treatment options for long lesions in patients with peripheral artery dise... 
Download PDFPrinter Friendly Version
07/11/16FDA Clears Expanded Indications for Medtronic NuVent(TM) EM Sinus Dilation System with Image Guidance
Clinical Study Conducted on Revision Subjects Support Expanded Indication for Patients with Previously Surgically Altered Tissue DUBLIN - July 11, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) clearance of NuVent(TM), an EM sinus dilation system, for patients with scarred, granulated, or previously surgically-altered tissue - an expansion of indications. Patients coming in for revision sinus surgery (RSS) have these tissue characteristics. NuVent is th... 
Download PDFPrinter Friendly Version
06/28/16Medtronic Announces Beacon Heart Failure Management Service, Furthering Its Commitment to Delivering Value in Healthcare
New Service Integrates Medtronic Device Data with Remote Patient Monitoring Solutions DUBLIN - June 28, 2016 - Medtronic plc (NYSE:MDT) today announced availability of its Beacon Heart Failure Management Service in the United States. This new service from Medtronic Care Management Services (MCMS) combines data from Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) devices with post-acute monitoring from MCMS, enabling providers to focus on heart f... 
Download PDFPrinter Friendly Version
06/27/16Medtronic to Expand Heart Failure Portfolio with Acquisition of Heartware International
Extends Clinical and Commercial Leadership Into Growing Circulatory Support Sector DUBLIN and FRAMINGHAM, Mass. - June 27, 2016 - Medtronic plc (NYSE: MDT), the global leader in medical technology, and HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, today announced that the companies have entered into a definitive merger agreement under which Medtronic will acquire He... 
Download PDFPrinter Friendly Version
06/24/16Medtronic Announces Double-Digit Increase in Cash Dividend; Reaches 40 Percent Payout Ratio
DUBLIN - June 24, 2016 - The board of directors of Medtronic plc (NYSE: MDT) today approved a 13 percent increase in its quarterly cash dividend, raising the quarterly amount to $0.43 per ordinary share. This would translate into an annual amount of $1.72 per ordinary share. Today's announcement marks the 39th consecutive year of an increase in the dividend payment for Medtronic, a constituent of the S&P 500 Dividend Aristocrats index. Including today's increase, Medtronic's dividend per share h... 
Download PDFPrinter Friendly Version
06/23/16World Stroke Organization and Medtronic Collaborate to Increase Stroke Awareness
The World Stroke Organization (WSO) today announced a global partnership with Medtronic plc (NYSE:MDT) to increase stroke awareness through several initiatives. The two organizations will work together to educate, raise awareness and support effective management of patients who have strokes. The partnership, announced at the 2016 Annual Scientific Session of the Chinese Stroke Association (CSA) and Tiantan International Stroke Conference (TISC) in Beijing, will focus on continued growth of stro... 
Download PDFPrinter Friendly Version
06/17/16New Clinical Study Will Evaluate MRI-Guided Laser Ablation for a Common Form of Epilepsy
Drug-Resistant Mesial Temporal Lobe Epilepsy Is the Focus of Medtronic's SLATE Study DUBLIN - June 17, 2016 - Medtronic plc (NYSE: MDT) announced today the U.S. Food and Drug Administration's (FDA) approval of the Investigational Device Exemption (IDE) application for the pivotal SLATE (Stereotactic Laser Ablation for Temporal Lobe Epilepsy) study. The clinical investigation is designed to support the expanded indication of the currently marketed Visualase(TM) MRI-Guided Laser Ablation Technolo... 
 Printer Friendly Version
06/10/16Medtronic Converts 125 Million Patient Days of Data Into Personalized Insights That Improve Diabetes Management
CareLink® Portfolio Updates, IBM Watson Partnership Progress and New Strategic Alliances Delivering Intelligent Data and Actionable Information at ADA 2016DUBLIN and NEW ORLEANS - June 10, 2016 - Delivering on its vision to transform care for the millions currently living with diabetes through intelligent data, Medtronic plc (NYSE:MDT) announced new product developments and technology partnerships at the American Diabetes Association (ADA) 76th Scientific Sessions that will create meaningful ins... 
Download PDFPrinter Friendly Version
06/10/16FIRE AND ICE Data Show Fewer Repeat Ablations and Hospitalizations for AF Patients Treated with Medtronic Cryoballoon
Secondary Analyses Presented at Cardiostim 2016 Highlight Positive, Real-World Patient Outcomes DUBLIN AND NICE, FRANCE - June 10, 2016 - Medtronic plc (NYSE: MDT) today announced findings from the secondary analyses of the FIRE AND ICE clinical trial that demonstrate significantly fewer repeat ablations and lower hospitalization rates for patients with paroxysmal atrial fibrillation (PAF) treated with the Arctic Front® Cryoballoon Catheter Family compared to the ThermoCool® line of radiofrequ... 
Download PDFPrinter Friendly Version
06/09/16New Data Further Demonstrate Safety Benefits for World's Smallest Pacemaker
Data Featured In Late-Breaking Trial Session at Cardiostim 2016 Show Micra TPS Safety Benefits Maintained Beyond Six Months DUBLIN and NICE, FRANCE - JUNE 9, 2016 - Medtronic plc (NYSE:MDT) today announced new results from the Medtronic Micra® Transcatheter Pacing System (TPS) Global Clinical Trial in a late-breaking trial session at CARDIOSTIM / EHRA EUROPACE 2016, the World Congress in Electrophysiology and Cardiac Techniques, in Nice, France. The new follow-up data on patients enrolled in ... 
Download PDFPrinter Friendly Version
06/08/16First Patient Treated with Medtronic Valiant Evo Thoracic Stent Graft System
Unique Next-Generation Device Evaluated in International Clinical Trial; First Procedure Performed at the University of Texas Health Science Center at Houston DUBLIN and HOUSTON - June 8, 2016 - Medtronic plc (NYSE: MDT) and the University of Texas Health Science Center at Houston (UTHealth) today announced the first patient enrolled in a clinical study assessing the Medtronic Valiant(TM) Evo Thoracic Stent Graft System for the minimally invasive repair of descending thoracic aortic aneurysms (... 
Download PDFPrinter Friendly Version
06/08/16Medtronic Announces Results of Early Feasibility Studies Supporting New Approach to ICD Therapy During Cardiostim 2016
Places ICD Leads Under Rib Cage, Outside Heart and Veins DUBLIN and NICE, FRANCE - JUNE 8, 2016 - Medtronic plc (NSYE: MDT) today announced results from several feasibility studies evaluating a new approach to implantable cardioverter defibrillator (ICD) therapy at CARDIOSTIM / EHRA EUROPACE 2016, the World Congress in Electrophysiology and Cardiac Techniques, in Nice, France. The Medtronic EV-ICD System, which currently is in development and not available for use or sale, is a new approach to... 
Download PDFPrinter Friendly Version
06/07/16Medtronic to Unveil Pivotal Trial Results for Hybrid Closed Loop System at American Diabetes Association 2016 Meeting
DUBLIN - June 7, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its schedule of notable sessions that will be presented at the 76th Scientific Sessions of the American Diabetes Association in New Orleans. Among the presentations are late breaking pivotal trial  results of the Hybrid Closed Loop system, pivotal trial results for the company's fourth generation sensor and further study of the company's SmartGuard(TM) technology. Hybrid Closed Loop system ... 
Download PDFPrinter Friendly Version
06/06/16Medtronic Outlines Future Growth Vision at Investor Day
DUBLIN and NEW YORK CITY - June 6, 2016 - Medtronic plc (NYSE: MDT), the global leader in medical technology, shared during its Investor Day today in New York City an overview of the company's position as a global healthcare leader with differentiated platforms to deliver attractive shareholder value, as well as its strategies for future growth. Chairman and CEO Omar Ishrak reiterated Medtronic's opportunity to address universal healthcare needs by improving clinical outcomes, expanding access, ... 
Download PDFPrinter Friendly Version
05/31/16Medtronic Strengthens Commitment to Asia Pacific
New Asia Pacific Regional Headquarters to Meet Healthcare Demands in the Region Establish Centre of Excellence with SingHealth to Enhance Patient Care for Diabetes SINGAPORE - May 31, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions, today announced the opening of its new Asia Pacific regional headquarters in Singapore. The new facility, which houses the Asia Pacific Service and Repair Centre of Excellence, will strengthen and support Medtronic ope... 
Download PDFPrinter Friendly Version
05/31/16Medtronic Reports Fourth Quarter and Fiscal Year 2016 Financial Results
Q4 Revenue of $7.6 Billion Grew 4% as Reported; 6% at Constant Currency Q4 GAAP Diluted EPS of $0.78; Q4 Non-GAAP Diluted EPS of $1.27 FY16 Revenue of $28.8 Billion Grew 42% as Reported; 7% on a Comparable, Constant Currency Basis Including the Q1 Extra Week Benefit FY16 GAAP Diluted EPS of $2.48; FY16 Non-GAAP Diluted EPS of $4.37 Company Sets Initial FY17 Revenue Growth Outlook and EPS Guidance   DUBLIN - May 31, 2016 - Medtronic plc (NYSE: MDT) today announced financial results... 
Download PDFPrinter Friendly Version
05/25/16The Nederlandse Obesitas Kliniek and Medtronic Join Forces in the Battle Against Morbid Obesity
DUBLIN and EINDHOVEN / ZEIST, THE NETHERLANDS - May 25, 2016 - The Nederlandse Obesitas Kliniek ('Dutch Obesity Clinic', NOK) and Medtronic plc (NYSE: MDT), a global leader in medical technology, services and solutions, today announced that Medtronic has signed an agreement to enter into a strategic alliance, via a majority ownership position in NOK, with the goal of enhancing NOK's ability to offer integrated, value-based healthcare solutions for the treatment of morbid obesity to more patients... 
Download PDFPrinter Friendly Version
05/25/16Medtronic and Qualcomm Collaborate to Aim to Improve Care and Health Outcomes for People with Type 2 Diabetes
Joint Development of Future Generation Continuous Glucose Monitoring (CGM) Systems Aims to Provide Actionable Insights to Help Deliver Integrated Diabetes Care DUBLIN and SAN DIEGO - May 25, 2016 - Medtronic plc (NYSE:MDT) and Qualcomm Incorporated (NASDAQ:QCOM) through its wholly-owned subsidiary, Qualcomm Life, Inc., today announced a global, multi-year collaboration to jointly develop future generation continuous glucose monitoring (CGM) systems that aim to improve health outcomes for peopl... 
Download PDFPrinter Friendly Version
05/19/16Medtronic Announces U.S. Launch of Spine Essentials Demonstrating Its Commitment to Create Value in Healthcare
New Platform Increases Efficiencies and Reduces Costs Associated with Common Spinal Surgery DUBLIN and DALLAS - May 19, 2016 - Medtronic plc (NYSE: MDT) announced the U.S. launch of Spine Essentials(TM), a new platform of spinal implants and instruments designed to make the most common cervical spine fusion procedures more efficient and help hospital systems manage costs, while maintaining quality. The goal of Spine Essentials is to help surgeons and their staffs streamline the most common spin... 
Download PDFPrinter Friendly Version
05/18/16Medtronic to Expand Minimally Invasive Therapy Portfolio with Acquisition of Gynecology Business from Smith & Nephew
DUBLIN - May 18, 2016 - Medtronic plc (NYSE: MDT) today announced it has signed a definitive agreement to acquire Smith & Nephew's (NYSE: SNN; LSE: SN) gynecology (GYN) business for approximately $350 million. This agreement reinforces Medtronic's dedication to expanding the use of less invasive treatments and demonstrates a commitment to improving options for women with abnormal uterine bleeding (AUB). The addition of the GYN portfolio will expand and strengthen Medtronic's minimally invasive s... 
Download PDFPrinter Friendly Version
05/17/16Medtronic EVP & MITG President Bryan Hanson to Speak at Jefferies Healthcare Conference
DUBLIN - May 17, 2016 -Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced that the company will participate in the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016, in New York City. Bryan C. Hanson, executive vice president and president of Medtronic's Minimally Invasive Therapies Group (MITG), will answer questions about the company beginning at 11:00 a.m. Eastern Daylight Time. A live audio webcast of the presentation will... 
Download PDFPrinter Friendly Version
05/17/16Medtronic CEO Omar Ishrak to Speak at Goldman Sachs Global Healthcare Conference
DUBLIN - May 17, 2016 -Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced that it will participate in the 37th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 7, 2016, in Rancho Palos Verdes, Calif. Omar Ishrak, chairman and chief executive officer of Medtronic, will answer questions about the company beginning at 9:20 a.m. Pacific Daylight Time. A live audio webcast of the presentation will be available on June 7, 2016... 
Download PDFPrinter Friendly Version
05/15/16Medtronic Statement on the Passing of Dr. Glen Nelson
MINNEAPOLIS - May 15, 2016 - Medtronic plc (NYSE:MDT) today issued the following statement regarding the passing of Dr. Glen Nelson: The 85,000 employees of Medtronic around the world are deeply saddened to learn of the passing of Dr. Glen Nelson.  Dr. Nelson served as the vice chairman of Medtronic from 1988 to 2002, and it is during this period that Medtronic rose to become the world's leading medical technology company - vastly expanding its medical technology portfolio and global prese... 
Download PDFPrinter Friendly Version
05/11/16Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2016
DUBLIN - May 11, 2016 - Medtronic plc (NYSE: MDT) announced today that it will report financial results for the fourth quarter and fiscal year 2016, on Tuesday, May 31, 2016. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at http://newsroom.medtronic.com. The news release will include summary financial information for the company's fourth quarter and fiscal year 2016, which ended on Friday, April 29, 2016. Medtronic will host a webcas... 
Download PDFPrinter Friendly Version
05/11/16Medtronic and the Vikings to Unveil "The Horn" Monument on Medtronic Plaza Outside U.S. Bank Stadium
New 38-Ton Artistic Landmark Represents the Spirit of Progress and Partnership That Together Lead Our Community to a Better Future MINNEAPOLIS - May 11, 2016 - Medtronic plc (NYSE: MDT) and the Minnesota Vikings today announced Medtronic's contribution of a new contemporary art sculpture on Medtronic Plaza, just outside the Vikings' new home at U.S. Bank Stadium. Funded privately by Medtronic and designed by Minneapolis design firm Alliiance, the monument is titled "The Horn." The Ho... 
Download PDFPrinter Friendly Version
05/10/16Medtronic Announces 2016 Institutional Investor and Analyst Meeting and Webcast
DUBLIN - May 10, 2016 - Medtronic plc (NYSE:MDT) announced today that the company will host its biennial Institutional Investor and Analyst Meeting on Monday, June 6, 2016, in New York City from 8:00 a.m. to approximately 3:15 p.m. Eastern Daylight Time. The meeting will include remarks from the Medtronic executive management team on the company's plans for delivering consistent and reliable revenue growth, strong operating and financial leverage, significant accessible free cash flow, and strat... 
Download PDFPrinter Friendly Version
05/06/16Medtronic Unveils Data Showing Feasibility of New Approach to ICD Therapy
Studies Presented at Heart Rhythm 2016 Provide Encouraging Results for ICD Lead Placement Under Ribs, Outside Heart and Veins DUBLIN and SAN FRANCISCO - May 6, 2016 - Medtronic plc (NYSE:MDT) today announced the results of several studies evaluating a novel approach to implantable cardioverter defibrillator (ICD) therapy at Heart Rhythm 2016, the Heart Rhythm Society's 37th Annual Scientific Sessions in San Francisco. The Medtronic EV-ICD System, which currently is in development and not ava... 
Download PDFPrinter Friendly Version
05/05/16New Data Further Support Medtronic Leadership in Leadless Pacing at Heart Rhythm 2016
Data Add to Body of Evidence Supporting World's Smallest Pacemaker            Micra TPS is First Leadless Pacemaker to Receive FDA Approval DUBLIN and SAN FRANCISCO - May 5, 2016 - Medtronic plc (NYSE:MDT) today announced clinical results highlighting the strong safety and performance profile of the miniaturized Micra® Transcatheter Pacing System (TPS) at Heart Rhythm 2016, the Heart Rhythm Society's 37th Annual Scientific Sessions in San Francisco. The Micra TPS is less than one-tenth the s... 
Download PDFPrinter Friendly Version
05/04/16Medtronic Welcomes Karen L. Parkhill as Its New Chief Financial Officer
Gary Ellis to Remain on Medtronic Executive Committee Until Retirement in Fiscal Year 2017 DUBLIN - May 4, 2016 - Medtronic plc (NYSE: MDT) announced today the appointment of Karen L. Parkhill as executive vice president and chief financial officer (CFO), effective June 20, 2016. Parkhill will succeed Gary L. Ellis in the CFO role and will report to Medtronic CEO Omar Ishrak. Today's announcement concludes an external search process conducted by the company to ensure a seamless succession ... 
Download PDFPrinter Friendly Version
05/03/16Late-Breaking Study Provides Evidence to Support Beneficial Seven-Year Clinical Outcomes and Patient Satisfaction for 2-Level Prestige LP(TM) Cervical Disc Patients
Study Represents Longest Patient Follow-Up Data for U.S. 2-Level Cervical Disc Patients DUBLIN and CHICAGO - May 3, 2016 - Medtronic plc (NYSE: MDT) today announced results of seven-year follow-up data demonstrating favorable clinical outcomes and patient satisfaction for the 2-level Prestige LP(TM) Cervical Disc compared to 2-level anterior cervical discectomy and fusion (ACDF). The Prestige LP Disc - currently indicated for single-level cervical disc disease causing nerve or spinal cord compr... 
Download PDFPrinter Friendly Version
05/02/16Medtronic Expands MRI-Compatible Portfolio with FDA Clearance of StrataMR(TM) Shunt System
Patients with Hydrocephalus and CSF Disorders Have Greater Access to Full Body MRI Scans with StrataMR DUBLIN - May 2, 2016 - Medtronic plc (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) clearance of StrataMR(TM) valves and shunts, an addition to Medtronic's family of Strata® Adjustable Valve Systems used in the treatment of patients with hydrocephalus and cerebrospinal fluid (CSF) disorders. The StrataMR system is intended to maintain its performance level setting durin... 
Download PDFPrinter Friendly Version
05/02/16Medtronic Receives FDA Approval for New Single-Chamber ICDs That Detect Atrial Fibrillation
Visia AF MRI(TM) SureScan® and Visia AF(TM)ICDs Treat Dangerous Heart Rhythms and Enable Physicians to Identify Patients at Increased Risk for Stroke and Heart Failure Due to AF DUBLIN - May 2, 2016 - Medtronic plc (NYSE: MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the Visia AF MRI(TM) SureScan® and Visia AF(TM) single-chamber implantable cardioverter defibrillators (ICDs). The Visia AF devices can detect previously undiagnosed and/or asymptomatic a... 
Download PDFPrinter Friendly Version
04/28/16Medtronic VenaSeal Closure System Demonstrates Long-Term Durability and Improved Quality of Life in Patients with Venous Reflux Disease
Medtronic Unveils Data for VenaSeal Closure System at Charing Cross and the International Vein Congress DUBLIN - April 28, 2016 - This week at the 2016 Charing Cross Symposium in London and the International Vein Congress in Miami, Medtronic plc (NYSE: MDT) unveiled clinical data for the VenaSeal(TM) closure system demonstrating consistent long-term durability and improved quality of life in patients with venous reflux disease. The new data presented included two-year outcomes from the VeClose... 
Download PDFPrinter Friendly Version
04/27/16Medtronic Demonstrates Commitment to EVAR in Comparison Study of ENGAGE Global Registry and Landmark EVAR 1 Trial
Clinical Integrity on Display through Longest Term Data of 1,200 Endurant AAA Stent Graft Patients DUBLIN AND LONDON - April 27, 2016 - Medtronic plc (NYSE:MDT) today reported on the ENGAGE global registry of experiences with the Endurant® AAA stent graft system from Medtronic with a reference to the landmark EVAR 1 Trial. ENGAGE represents the most robust post-market registry ever initiated in the study of endovascular aortic repair (EVAR) with more than 1,200 patients at 79 sites across six c... 
Download PDFPrinter Friendly Version
04/26/16Medtronic IN.PACT Admiral DCB Maintains Durable, Consistent and Safe Outcomes in Challenging Peripheral Cases
New Rigorous Analyses Presented at Charing Cross Reinforce Efficacy in Females, Chronic Total Occlusions and Patients with Diabetes; Data Details Unique, Sustained Benefit with IN.PACT Admiral DCB DUBLIN and LONDON - April 26, 2016 - Medtronic plc (NYSE: MDT) today added to its robust body of clinical evidence supporting the IN.PACTTM AdmiralTM drug-coated balloon (DCB) with several new presentations that showed durable and consistent clinical outcomes in the most challenging patients with peri... 
Download PDFPrinter Friendly Version
04/21/16Medtronic Launches New Endoscopic Ablation Catheter for Barrett's Esophagus
BarrxTM 360 Express RFA Balloon Catheter's Adjustable Custom Fit Provides Targeted Precision Therapy - Allowing Physician Ease and Efficiency DUBLIN - April 21, 2016 - Medtronic (NYSE: MDT) today announced the launch of the new BarrxTM 360 Express radiofrequency ablation (RFA) balloon catheter, which can help in the treatment of Barrett's esophagus. The Barrx 360 Express catheter, with its self-adjusting circumferential RFA catheter, lets gastroenterologists and surgeons provide RFA treatment ... 
Download PDFPrinter Friendly Version
04/20/16Real-World Study Shows 72 Percent of Atrial Fibrillation Would Have Gone Undiagnosed in Stroke Patients if Cardiac Monitoring Had Been Limited to 30 Days
Findings Demonstrate Detection of Atrial Fibrillation in Cryptogenic Stroke Patients with Medtronic Insertable Cardiac Monitor DUBLIN and VANCOUVER - APRIL 20, 2016 - Medtronic plc (NSYE: MDT) today announced one-year results from a real-world study of patients who had a cryptogenic stroke, or stroke of unknown cause. The study found that the Reveal LINQ(TM) Insertable Cardiac Monitor (ICM) detected atrial fibrillation (AF) at a greater rate than previously reported in a randomized controlled c... 
Download PDFPrinter Friendly Version
04/20/16Medtronic Announces Worldwide Voluntary Recall for Battery Pack in Covidien Oridion Labeled Capnostream(TM)20 and Capnostream(TM)20p Patient Monitors
DUBLIN - April 20, 2016 - Medtronic is notifying customers worldwide of a voluntary recall for the battery pack used in its Covidien Oridion labeled Capnostream(TM)20 and Capnostream(TM)20p Patient Monitors. This voluntary recall is being conducted due to a battery manufacturing defect that may increase the risk of thermal damage in the battery pack. The scope of this recall includes battery pack model numbers 016400 and 010520. These packs were manufactured by a contract manufacturer between Ap... 
Download PDFPrinter Friendly Version
04/18/16Material in Medtronic Leads Inducted into Space Technology Hall of Fame®
Medtronic Applied NASA Technology into Its Cardiac Devices DUBLIN and COLORADO SPRINGS, COLO. - April 18, 2016 - The Space Foundation has inducted NASA Langley Research Center-Soluble Imide (LaRC-SI) - used in Medtronic plc (NYSE: MDT) leads connected to implantable cardiac devices - into the Space Technology Hall of Fame®. The ceremony was held during the Space Foundation's 32nd Space Symposium in Colorado Springs, Colo. LaRC-SI is an insulation material developed by researchers at the NASA (... 
Download PDFPrinter Friendly Version
04/14/16Medtronic Announces the Pricing Terms of Its Cash Tender Offer of Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
DUBLIN - April 14, 2016 - Medtronic plc (the "Company") (NYSE: MDT) today announced the pricing terms of the previously-announced cash tender offer by its wholly-owned subsidiaries, Medtronic, Inc. ("Medtronic, Inc.") and Covidien International Finance S.A. ("CIFSA" and, together with Medtronic, Inc., the "Offerors"), for up to $3 billion combined aggregate purchase price (excluding accrued and unpaid interest to, but not including, the applicable settleme... 
Download PDFPrinter Friendly Version
04/14/16Medtronic Announces the Early Results and Upsizing of Its Cash Tender Offer for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
DUBLIN - April 14, 2016 - Medtronic plc (the "Company") (NYSE: MDT) today announced that, pursuant to the previously-announced cash tender offer by its wholly-owned subsidiaries, Medtronic, Inc. ("Medtronic, Inc.") and Covidien International Finance S.A. ("CIFSA" and, together with Medtronic, Inc., the "Offerors") for the Notes identified in the table below (the "Notes"), approximately $5.8 billion in aggregate principal amount of Notes were vali... 
Download PDFPrinter Friendly Version
04/13/16New Data Shows Benefits of Medtronic Insulin Pumps for People with Type 2 Diabetes
Study Shows Insulin Pumps Safely Provided Significant, Sustainable and Reproducible Improvements in Glucose Control in Comparison to Multiple Daily Injections DUBLIN - April 13, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the publication of new data in Diabetes, Obesity and Metabolism from the continuation phase of the OpT2mise study, providing further clinical evidence in support of insulin pumps for people with insulin-requiring type 2 diabetes.  ... 
Download PDFPrinter Friendly Version
04/10/16Medtronic Responds to Star Tribune Article Regarding INFUSE Bone Graft
MINNEAPOLIS - April 10, 2016 - This weekend, an article was published in the Minneapolis Star Tribune that criticized Medtronic's handling of data collected during a retrospective chart review (RCR) of INFUSE Bone Graft between 2006-2008. The article makes insinuations that are false, and fails to include important information regarding the RCR and Medtronic's actions. Medtronic provided the Star Tribune an extensive account of what transpired around the RCR, both in person and in writing, whic... 
Download PDFPrinter Friendly Version
04/06/16FDA Approves World's Smallest Pacemaker for U.S. Patients
The Medtronic Micra® TPS is the First Transcatheter Pacemaker Approved in the U.S. Gives Patients Access to the Most Advanced Pacing Technology at One-Tenth the Size of Traditional Devices DUBLIN - April 6, 2016 - Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval of the world's smallest pacemaker, the Medtronic Micra Transcatheter Pacing System (TPS). The Micra TPS is the first FDA-approved product with miniaturized pacing technology. It... 
Download PDFPrinter Friendly Version
04/06/16Medtronic Statement on U.S. Department of Treasury's Recent Temporary and Proposed Regulations
DUBLIN - April 6, 2016 - Medtronic plc (NYSE: MDT) has conducted a preliminary review of the United States Department of Treasury Temporary and Proposed Regulations issued on April 4, 2016, which are designed to address certain concerns around transactions referred to by Treasury as "tax inversions" and "earnings stripping." Medtronic has concluded that the Temporary and Proposed Regulations do not have a material financial impact on any transaction undertaken by the company.... 
Download PDFPrinter Friendly Version
04/04/16First-Ever Medtronic Harmony(TM) Transcatheter Pulmonary Valve Data Shows Positive Procedural Success In Early Feasibility Study
Encouraging Early Outcomes from Rigorously Designed Study Set the Stage for IDE DUBLIN and CHICAGO - April 4, 2016 - Medtronic plc (NYSE: MDT) today announced first-ever clinical data on the Harmony(TM) Transcatheter Pulmonary Valve (TPV) from its early feasibility study, demonstrating positive initial outcomes at six-months in patients with an indication for pulmonary valve restoration. The initial results were presented during the 65th Annual Scientific Session of the American College of Cardi... 
Download PDFPrinter Friendly Version
04/04/16Medtronic Arctic Front® Cryoballoon Catheters Meet Non-Inferiority Goal in Head-to-Head Trial Presented at ACC Scientific Sessions and Published in The New England Journal of Medicine
Cryoballoon Comparable in Safety and Effectiveness as Current Standard of Care Ablation Technology DUBLIN and CHICAGO - April 4, 2016 - Medtronic plc (NYSE: MDT) today announced positive results from the landmark FIRE AND ICE clinical trial, which demonstrated comparable safety and effectiveness for its Arctic Front® Cryoballoon Catheter Family compared to the ThermoCool® line of radiofrequency (RF) ablation catheters for the treatment of symptomatic paroxysmal atrial fibrillation (AF). The stud... 
Download PDFPrinter Friendly Version
04/03/16Medtronic CoreValve® System Maintains Survival Advantages Over Surgery in High Risk Aortic Stenosis Patients at Three Years
New Data at ACC.16 First to Show Superior, Longer-Term Outcomes for Self-Expanding TAVR vs. SAVR at Three Years  Results Published Simultaneously in the Journal of American College of Cardiology (JACC) DUBLIN and CHICAGO - April 3, 2016 - Medtronic plc (NYSE: MDT) today announced new data from the High Risk Study of the CoreValve U.S. Pivotal Trial that show superior clinical outcomes for transcatheter aortic valve replacement (TAVR) with the CoreValve® System compared to surgical aortic valve r... 
Download PDFPrinter Friendly Version
04/03/16Medtronic Announces Early Data and Completes Enrollment in CE Mark Cohort in Drug-Filled Stent Trial
RevElution Trial with Next-Gen Polymer-Free Stent Continues to Show Excellent Rapid Healing and Controlled Drug Delivery at ACC.16  DUBLIN and CHICAGO - April 3, 2016 - Medtronic plc (NYSE: MDT) announced new clinical data today from one of the endpoints in the RevElution Trial for its novel, next-generation Drug-Filled Stent (DFS). These new data showed rapid vessel healing without inflammation in Optical Coherence Tomography (OCT) data of the complete one-month follow-up patient cohort. The re... 
Download PDFPrinter Friendly Version
04/02/16Medtronic CoreValve® System Demonstrates Superior Survival to Surgery in Aortic Stenosis Patients with Lower STS Scores
New Sub-study at ACC.16 from the CoreValve U.S. High Risk Trial Shows Exceptional Valve Performance for the Self-Expanding Transcatheter Heart Valve at Two Years DUBLIN and CHICAGO - April 2, 2016 - Medtronic plc (NYSE: MDT) today unveiled new clinical data on the self-expanding CoreValve® System from the High Risk Study of the CoreValve U.S. Pivotal Trial, showing superior outcomes in survival for transcatheter aortic valve replacement (TAVR) compared to surgery at two years for the subgroup of... 
Download PDFPrinter Friendly Version
03/31/16Medtronic Announces Cash Tender Offer for Up to $2.75 Billion Aggregate Purchase Price of Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A.
DUBLIN - March 31, 2016 - Medtronic plc (the "Company") (NYSE: MDT) today announced the commencement of a cash tender offer (the "Tender Offer") by its wholly-owned subsidiaries, Medtronic, Inc. ("Medtronic, Inc.") and Covidien International Finance S.A. ("CIFSA" and, together with Medtronic, Inc., the "Offerors"), for up to $2.75 billion combined aggregate purchase price (excluding accrued and unpaid interest to, but not including, the applicabl... 
Download PDFPrinter Friendly Version
03/31/16First Patients Enrolled in Medtronic Trial in Low-Risk Aortic Stenosis Patients
DUBLIN - March 31, 2016 - Medtronic plc (NYSE: MDT) today announced that the first patients were enrolled in the expanded indication trial for the CoreValve® Evolut® R System, the first and only next-generation recapturable, self-expanding transcatheter aortic valve replacement (TAVR) system commercially available in the United States. The first patients were enrolled at PinnacleHealth CardioVascular Institute in Harrisburg, PA. The heart team led by Mubashir Mumtaz, M.D., F.A.C.S., F.A.C.C. ch... 
Download PDFPrinter Friendly Version
03/31/16Medtronic Receives Expanded Indication From FDA for Pillcam(TM) Colon 2 Capsule
Potentially Reaching More Patients at Risk for Colon Cancer  DUBLIN - March 31, 2016 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) cleared PillCam(TM) COLON 2 capsule for an expanded indication for use. The PillCam(TM) COLON 2 capsule is the only non-invasive diagnostic test that directly visualizes the colon for the evaluation of polyps in patients who are at major risks for colonoscopy or moderate sedation. The PillCam(TM) capsule- a vitamin-sized... 
Download PDFPrinter Friendly Version
03/30/16Medtronic Launches Percutaneous Tibial Neuromodulation Delivered by the NURO System for the Treatment of Overactive Bladder (OAB)
New Medtronic Treatment Targets Underlying Bladder and Brain Miscommunication and Could Bring Desperately Needed Relief to Tens of Millions Struggling with OAB DUBLIN - March 30, 2016 - Medtronic plc (NYSE: MDT) today announced the launch of its NURO(TM) System that delivers percutaneous tibial neuromodulation (PTNM) for the treatment of overactive bladder (OAB) with symptoms of urinary urgency, urinary frequency, and urge incontinence. PTNM, a minimally invasive, periodic, office-based proced... 
Download PDFPrinter Friendly Version
03/29/16Medtronic Foundation Seeks Runners Benefitting from Medical Technology for 2016 "Global Heroes" Team
Applications now open: www.medtronic.com/globalheroes Selected runners receive entry and travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October 2016 Cancer, Stroke, Obesity added to list of eligible medical conditions DUBLIN - March 29, 2016 - Applications are now open for the 2016 Global Heroes running team. Every October since 2006, the Medtronic Foundation and Twin Cities In Motion have brought people from around the world to Minnesota to be part of a unique collect... 
Download PDFPrinter Friendly Version
03/21/16Medtronic EVP & President, Hooman Hakami to Speak at Deutsche Bank Medtech Boot Camp Healthcare Conference
DUBLIN - Mar 21, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced it will participate in the Deutsche Bank MedTech Boot Camp on Monday, March 21, 2016, in Boston, Massachusetts. Homan Hakami, executive vice president and president of Medtronic's Diabetes Group, will make a presentation on the company beginning at 2:05 p.m. EDT (1:05 p.m. CDT). A live audio webcast of the presentation will be available on March 21, 2016, by clickin... 
Download PDFPrinter Friendly Version
03/17/16Medtronic Proposes Proxy Access
DUBLIN - March 17, 2016 - Medtronic plc (NYSE: MDT) will put forth a board proposal supporting the adoption of proxy access in its 2016 proxy statement.  Proxy access would allow long-term shareholders the ability to nominate their own director candidates for election to the Board of Directors and have such director candidates included on the company's proxy card, along with any candidates nominated by the Board of Directors. Pending shareholder approval, the board proposal to amend the company... 
Download PDFPrinter Friendly Version
03/10/16First European Patients Enroll in Medtronic International Lung Cancer Study
NAVIGATE Study Assesses Impact of Minimally Invasive Technology to Aid in Early Diagnosis and Treatment of Lung Cancer DUBLIN - March 10, 2016 - Committed to technologies that assist in the goal of reducing lung cancer morbidity worldwide, Medtronic (NYSE: MDT) today announced European enrollment in the NAVIGATE clinical trial. This 2,500-patient international study will assess the long-term impact of its superDimension(TM) navigation system as an aid in early detection of lung cancer and subse... 
Download PDFPrinter Friendly Version
03/07/16Medtronic EVP & CFO Gary Ellis to Speak at Barclays Healthcare Conference
DUBLIN - Mar 7, 2016 - Medtronic plc  (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced it will participate in the Barclays Global Healthcare Conference on Thursday, March 17, 2016, in Miami Beach, Florida. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation on the company beginning at 9:30 a.m. EDT (8:30 a.m. CDT). A live audio webcast of the presentation will be available on March 17, 2016, by click... 
Download PDFPrinter Friendly Version
03/07/16Medtronic Enrolls First Patients in Clinical Study to Evaluate the CoreValve(TM) Evolut(TM) R System in 'Real-World' Setting
FORWARD Clinical Study Designed to Confirm the Exceptional Results Achieved in the Evolut R CE Study DUBLIN - March 7, 2016 - Medtronic plc (NYSE: MDT) today announced the first patients enrolled in the Evolut R FORWARD Clinical Study, a global, multi-center, single-arm, prospective study of up to 1,000 patients, to evaluate performance outcomes using the CoreValve(TM) Evolut(TM) R System in everyday clinical practice. A next-generation, recapturable and repositionable transcatheter aortic val... 
Download PDFPrinter Friendly Version
03/04/16Medtronic EVP & President Michael J. Coyle to Speak at Cowen Healthcare Conference
DUBLIN - Mar 4, 2016 - Medtronic plc  (NYSE:MDT), a global leader in medical technology, services, and solutions, today announced it will participate in the 36th Annual Cowen & Company Healthcare Conference on Tuesday, March 8, 2016, in Boston, Massachusetts. Mike Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group, will make a formal presentation on the company beginning at 11:20 a.m. EST (10:20 a.m. CST). A live audio webcast of the presentation will be av... 
Download PDFPrinter Friendly Version
03/03/16Medtronic the First to Offer Complete Portfolio of Full-Body MR Conditional Neurostimulation Systems for Chronic Pain
FDA Approval of Medtronic Specify® SureScan® MRI Surgical Leads Rounds Out Exclusive Portfolio Designed for Access to Full-Body MRI[*] DUBLIN - March 3, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of Specify® SureScan® MRI surgical leads, which are indicated for use as part of Medtronic implanted neurostimulation (also known as spinal cord stimulation, or SCS) systems for chronic pain. In 2013, Medtronic introduced the only implantable neuro... 
Download PDFPrinter Friendly Version
03/01/16Medtronic Reports Third Quarter Financial Results
Revenue of $6.9 Billion Grew 6% on a Comparable, Constant Currency Basis; 61% as Reported  NON-GAAP Diluted EPS of $1.06; GAAP Diluted EPS of $0.77 Adjusted Free Cash Flow of $1.8 Billion; GAAP Cash Flow from Operations of $1.8 Billion DUBLIN - March 1, 2016 - Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2016, which ended January 29, 2016. Unless otherwise noted, all revenue growth rates in this press release are stated on a compara... 
Download PDFPrinter Friendly Version
02/22/16Medtronic Receives FDA Approval for Expanded Indication Trial in Low-Risk Aortic Stenosis Patients
DUBLIN - February 22, 2016 - Medtronic plc (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication trial for the CoreValve® Evolut® R System, the first and only next-generation recapturable, self-expanding transcatheter aortic valve replacement (TAVR) system commercially available in the United States. Patients with aortic stenosis, who are at a low surgical mortality risk as determined by a heart team, will be enrolled in the trial. Enrollme... 
Download PDFPrinter Friendly Version
02/22/16Medtronic Receives CE Mark for Full Line of Cardiac Resynchronization Therapy-Defibrillators Compatible with MRI Scans
Now Offering Both 1.5 and 3 Tesla Indications for MR-Conditional ICMs, Pacemakers, ICDs and CRT-Ds DUBLIN - February 22, 2016 - Medtronic plc (NYSE:MDT) today announced that it has received CE (Conformité Européenne) Mark for the first and only cardiac resynchronization therapy defibrillators (CRT-Ds) approved for 3 Tesla (T) magnetic resonance imaging (MRI) scans, providing CRT-D patients with access to the most advanced imaging diagnostic procedures available. This full line of CRT-Ds - also... 
Download PDFPrinter Friendly Version
02/19/16Medtronic Named Among the World's Most Admired Companies by Fortune Magazine
Ranked Second Within Medical Products and Equipment Category DUBLIN - February 19, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, has been designated as one of the World's Most Admired Companies by FORTUNE Magazine. Within the Medical Products and Equipment industry category, Medtronic ranked second globally. This 2016 listing was released today, and is considered one of the leading measures of corporate reputation among the world's largest com... 
Download PDFPrinter Friendly Version
02/19/16Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2016
DUBLIN - February 19, 2016 - Medtronic plc (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2016 on Tuesday, March 1, 2016. A news release will be issued at approximately 5:45 a.m. Central Standard Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for the third fiscal quarter, which ended January 29, 2016. Medtronic will host a webcast at 7:00 a.m. Central Standar... 
Download PDFPrinter Friendly Version
02/19/16Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2016
DUBLIN - February 19, 2016  - The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2016 fourth quarter cash dividend of $0.38 per ordinary share, representing a 25 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in June 2015.  Medtronic has increased its annual dividend payment for the past 38 consecutive years, and is a constituent of the S&P 500 Dividend Aristocrats index.  The divide... 
Download PDFPrinter Friendly Version
02/18/16Meta-Analysis Shows Medtronic's Solitaire(TM) Stent Retriever Device Improves Functional Outcomes for Acute Ischemic Stroke Patients; Reduced Mortality in Patients 80+
SEER Pooled, Patient-Level Analysis of SWIFT PRIME, EXTEND-IA, ESCAPE and REVASCAT Shows Safety and Efficacy of Solitaire Device DUBLIN - February 18, 2016 - A meta-analysis published online today in Stroke and presented at the International Stroke Conference (ISC) in Los Angeles, Calif., found that the addition of Medtronic plc's (NYSE: MDT) Solitaire(TM) stent retriever to current pharmaceutical treatment (IV-tPA) significantly improves functional outcomes in patients suffering stroke. Safety... 
Download PDFPrinter Friendly Version
02/17/16FDA Approves Medtronic Deep Brain Stimulation for People with Parkinson's Disease with Recent Onset of Motor Complications
Approval Expands Population of Individuals Who May Benefit From the Proven Therapy DUBLIN - February 17, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of Medtronic Deep Brain Stimulation (DBS) Therapy for use in people with Parkinson's disease of at least four years duration and with recent onset of motor complications, or motor complications of longer-standing duration that are not adequately controlled with medication. In 2002, the FDA initi... 
Download PDFPrinter Friendly Version
02/12/16NICE Recommends Medtronic Integrated Sensor-Augmented Insulin Pump As the Only Therapy System to Manage Glucose Levels in Type 1 Diabetes
The NICE guidance reviewed two sensor-augmented insulin pump therapy systems and recommends the MiniMed® Paradigm Veo(TM) system for managing glucose levels in people with Type 1 diabetes.1 The MiniMed Paradigm Veo and the MiniMed 640G sensor-augmented insulin pump therapy systems can help to protect against severe hypoglycemia in people with Type 1 diabetes by continuously monitoring glucose levels. NICE concluded that the adoption of Medtronic technology has the potential to save a UK health s... 
Download PDFPrinter Friendly Version
02/09/16First Patient Treated with Medtronic Valiant TAAA Stent Graft System in Thoracoabdominal Aortic Aneurysm Study
Sanford Health in Collaboration with Medtronic Leads Global Efforts to Address Challenging Vascular Condition DUBLIN and SIOUX FALLS, S.D. - February 9, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions and Sanford Health, one of the nation's largest health care systems, today announced the first patient enrolled in a clinical study using the Medtronic Valiant® TAAA Stent Graft System for minimally invasive repair of thoracoabdominal aortic aneurysm.... 
Download PDFPrinter Friendly Version
02/05/16Medtronic's iPro(TM)2 Professional CGM Shows Benefits for People with Type 2 Diabetes
iPro2 Professional CGM Provides Information to Help Physicians Optimize Care for Their Patients Regardless of Their Diabetes Therapy MILAN - February 5, 2016 - A retrospective analysis of the iPro2 Professional CGM from Medtronic plc (NYSE:MDT), the global leader in medical technology, demonstrates that patients with type 2 diabetes experience high rates of glycemic variability, hypoglycemia and hyperglycemia regardless of whether they manage their diabetes with diet/exercise, oral medication o... 
Download PDFPrinter Friendly Version
02/05/16Medtronic First to Receive FDA Approval for MR-Conditional Cardiac Resynchronization Therapy-Defibrillators
Amplia MRI(TM) and Compia MRI(TM) CRT-Ds, Approved for Patients with Heart Failure, Can Safely Undergo Full Body MRI Scans DUBLIN - Feb. 5, 2016 - Medtronic plc (NYSE:MDT) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the first and only magnetic resonance imaging (MRI) conditional cardiac resynchronization therapy defibrillators (CRT-Ds) for the treatment of heart failure. The Medtronic Amplia MRI(TM) Quad CRT-D SureScan® and Compia MRI(TM) Quad CRT-... 
Download PDFPrinter Friendly Version
02/01/16Medtronic Adds New Resolute Onyx(TM) Drug-Eluting Stent Sizes and Expands Indications
New Extra-Large Vessel Stent Sizes and Indications in the EU Expand Treatment Options for Patients with Coronary Artery Disease DUBLIN - February 1, 2016 - Medtronic plc (NYSE: MDT) today announced the recent CE (Conformité Européene) Mark and commercial launch for an expanded size matrix of the Resolute Onyx DES, a next generation drug-eluting stent that is now available in 4.5mm and 5.0mm diameter sizes. The CE Mark also approved several new product indications including treatment of left mai... 
Download PDFPrinter Friendly Version
02/01/16Medtronic Adds Life-Extending Dialysis Portfolio to Recently Formed Renal Care Solutions Business with Acquisition of Bellco
DUBLIN - February 1, 2016 - Furthering its commitment to improve outcomes, expand therapy access, and optimize costs and efficiencies in end stage renal disease (ESRD), Medtronic plc (NYSE: MDT) today announced it acquired privately-held Bellco, a pioneer in hemodialysis treatment solutions.  Bellco's portfolio bolsters Medtronic's legacy renal access business and will be a foundational component of the company's recently formed Renal Care Solutions business.  Bellco has created therapies and ... 
Download PDFPrinter Friendly Version
01/30/16Medtronic Presents Innovation Village – The First-Of-Its-Kind Initiative – At The 2nd Medical Device Summit in New Delhi
NEW DELHI – 30 January 2016 – For the second year in a row, Medtronic hosted the Medical Device Summit in New Delhi on 30th January 2016, bringing together leading national and international healthcare practitioners, research scientists, and business leaders. The theme of this year’s Summit was “Technological Innovation,” and speakers shared their views and latest updates on innovation and clinical outcomes driving the evolution of the healthcare ecosystem. The Summit ad... 
Download PDFPrinter Friendly Version
01/29/16Medtronic to Present Data on Micra® Transcatheter Pacing System at Upcoming FDA Advisory Committee Meeting
DUBLIN - January 29, 2016 - Medtronic plc (NYSE: MDT) will present data on the world's smallest pacemaker, the Micra® Transcatheter Pacing System (TPS), at the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee on Feb. 18, 2016, in Gaithersburg, Maryland. According to the FDA, the committee will meet to discuss and make recommendations on clinical trial research, post-approval study design, and physician training requirements for le... 
Download PDFPrinter Friendly Version
01/13/16Medtronic Expands Pain Therapies Portfolio with the Launch of OsteoCool(TM) RF Ablation System
Minimally-Invasive Procedure Brings Relief to Patients Suffering from Painful Spine Tumors DUBLIN - January 13, 2016 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance and U.S. launch of the OsteoCool(TM) RF Ablation System.  For physicians who treat patients with painful spine metastases, the OsteoCool System is the only cooled radiofrequency (RF) ablation technology that offers simultaneous, dual-probe capabilities - providing procedural flex... 
Download PDFPrinter Friendly Version
01/11/16Medtronic Updates Capital Allocation Plans and Fiscal 2016 EPS Guidance
Executing Incremental $5 Billion Share Repurchase Tightening EPS Guidance Due to Benefit of U.S. R&D Tax Credit DUBLIN - Jan 11, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services, and solutions, today updated its capital allocation plans for the approximately $9.3 billion resulting from the previously announced September 2015 internal reorganization as part of the company's integration of Covidien legal entities. Separately, the company today reiterated its re... 
Download PDFPrinter Friendly Version
01/11/16Medtronic IN.PACT Admiral DEB Receives CE Mark for Treatment of AV Access In Patients with End-Stage Renal Disease
IN.PACT Admiral DEB with 40 Centimeter Catheter Enables Physicians to Maintain Arteriovenous (AV) Access in Patients Undergoing Hemodialysis DUBLIN - January 11, 2016 - Medtronic plc (NYSE:MDT), a global leader in medical technology, services and solutions, today announced that the IN.PACT® Admiral® drug eluting balloon (DEB) (also known as the IN.PACT Admiral drug-coated balloon (DCB) in non-European markets) has received CE (Conformité Européene) Mark for arteriovenous (AV) access to help ma... 
Download PDFPrinter Friendly Version
01/11/16Medtronic and Chengdu Sign Insulin Pump Manufacturing Agreement
New Agreement Will Help Expand Access to Advanced Diabetes Therapies in China DUBLIN and CHENGDU, China - January 11, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, has formed a partnership with the Chengdu municipal government to manufacture and deploy advanced diabetes therapies in Chengdu, China.  As part of the agreement, Medtronic will invest in a manufacturing facility for a next generation sensor augmented pump system with SmartGuard(TM) technology to help pro... 
Download PDFPrinter Friendly Version
X